$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2019 Q2 Form 10-Q Financial Statement

#000114420419027322 Filed on May 20, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $61.60K $50.80K $57.60K
YoY Change 1183.33% 429.17%
Cost Of Revenue $19.20K $14.24K $29.05K
YoY Change 659.49% 493.29% 190.5%
Gross Profit $42.40K $36.56K $28.55K
YoY Change 1766.2% 407.79%
Gross Profit Margin 68.83% 71.97% 49.57%
Selling, General & Admin $312.6K $282.0K $257.3K
YoY Change 0.83% 40.99% 71.51%
% of Gross Profit 737.19% 771.23% 901.12%
Research & Development $0.00 $0.00 $86.34K
YoY Change -100.0% -100.0% -4.07%
% of Gross Profit 0.0% 0.0% 302.42%
Depreciation & Amortization $5.280K $5.290K $21.14K
YoY Change -47.1% 111.4%
% of Gross Profit 12.45% 14.47% 74.05%
Operating Expenses $317.9K $287.3K $348.9K
YoY Change 0.24% 35.87% 45.38%
Operating Profit -$275.5K -$250.7K -$320.4K
YoY Change -12.51% 22.76% 33.48%
Interest Expense $187.2K $454.5K $2.343M
YoY Change -54.67% 137.6% -290.48%
% of Operating Profit
Other Income/Expense, Net -$546.7K
YoY Change -92.59%
Pretax Income -$88.23K -$797.4K $1.934M
YoY Change -98.63% -89.49% -230.7%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$88.23K -$797.4K $1.934M
YoY Change -98.63% -89.49% -230.7%
Net Earnings / Revenue -143.23% -1569.62% 3358.25%
Basic Earnings Per Share
Diluted Earnings Per Share -$12.43K -$123.8K $368.8K
COMMON SHARES
Basic Shares Outstanding 1.043B 890.6M 830.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $204.1K $419.5K $304.1K
YoY Change 104.11% 319.48% 2940.6%
Cash & Equivalents $419.5K $304.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $1.000K $163.00 $9.600K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $205.1K $419.6K $313.7K
YoY Change 94.78% 274.98% 1595.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $152.9K $158.2K $163.5K
YoY Change -12.14% -11.16% -11.45%
TOTAL ASSETS
Total Short-Term Assets $205.1K $419.6K $313.7K
Total Long-Term Assets $152.9K $158.2K $163.5K
Total Assets $358.1K $577.9K $477.2K
YoY Change 28.16% 99.26% 134.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $320.4K $342.8K $331.8K
YoY Change 17.45% 49.04% 39.68%
Accrued Expenses $91.20K $69.59K $21.64K
YoY Change 127.69% 131.97% -6.48%
Deferred Revenue
YoY Change
Short-Term Debt $1.070M $0.00 $0.00
YoY Change 722.95% -100.0% -100.0%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $2.995M $4.183M $4.472M
YoY Change -72.45% -49.12% 83.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.995M $4.183M $4.472M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.995M $4.183M $4.472M
YoY Change -72.45% -49.18% 83.32%
SHAREHOLDERS EQUITY
Retained Earnings -$17.88M -$17.08M
YoY Change 398.63%
Common Stock $14.27M $13.08M
YoY Change 999.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.637M -$3.605M -$3.995M
YoY Change
Total Liabilities & Shareholders Equity $358.1K $577.9K $477.2K
YoY Change 28.16% 99.26% 134.88%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$88.23K -$797.4K $1.934M
YoY Change -98.63% -89.49% -230.7%
Depreciation, Depletion And Amortization $5.280K $5.290K $21.14K
YoY Change -47.1% 111.4%
Cash From Operating Activities -$329.4K -$273.0K -$1.052M
YoY Change 31.74% 65.53% 776.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 114.0K 388.4K 1.343M
YoY Change -54.4% 53.2% 1120.57%
NET CHANGE
Cash From Operating Activities -329.4K -273.0K -1.052M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 114.0K 388.4K 1.343M
Net Change In Cash -215.4K 115.4K 290.4K
YoY Change -246657108497749500.0% 30.25% -3003.6%
FREE CASH FLOW
Cash From Operating Activities -$329.4K -$273.0K -$1.052M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Cash
Cash
419477
CY2018Q4 us-gaap Cash
Cash
304056
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
163
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9600
CY2019Q1 us-gaap Assets Current
AssetsCurrent
419640
CY2018Q4 us-gaap Assets Current
AssetsCurrent
313656
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
158219
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
163505
CY2019Q1 us-gaap Assets
Assets
577859
CY2018Q4 us-gaap Assets
Assets
477161
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
342799
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
331838
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69592
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21640
CY2019Q1 us-gaap Management Fee Payable
ManagementFeePayable
153082
CY2018Q4 us-gaap Management Fee Payable
ManagementFeePayable
198082
CY2019Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1079414
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
682056
CY2019Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
10800
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
10800
CY2019Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2526952
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3227382
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4182639
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4471798
CY2019Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2019Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0
CY2018Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0
CY2019Q1 us-gaap Liabilities
Liabilities
4182639
CY2018Q4 us-gaap Liabilities
Liabilities
4471798
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
1007489
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
902711
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
13263430
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
12180985
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17878699
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17081333
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-3604780
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-3994637
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
577859
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
477161
CY2019Q1 celz Working Capital Deficit
WorkingCapitalDeficit
3762999
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3227382
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
925329
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1247434
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-378325
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2526952
CY2019Q1 us-gaap Revenues
Revenues
50800
CY2018Q1 us-gaap Revenues
Revenues
9600
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
14239
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
2400
CY2019Q1 us-gaap Gross Profit
GrossProfit
36561
CY2018Q1 us-gaap Gross Profit
GrossProfit
7200
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3200
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
281974
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
202930
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5286
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5286
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
287260
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
211416
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-250699
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-204216
CY2019Q1 us-gaap Interest Expense
InterestExpense
454542
CY2018Q1 us-gaap Interest Expense
InterestExpense
191308
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-265167
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7036772
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-546667
CY2019Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
658005
CY2019Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
113158
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7382364
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-797366
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7586580
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
965679771
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
188131817
CY2019Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-357292
CY2018Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-154284
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-797366
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7586580
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7586580
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1877
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5286
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5286
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
396240
CY2018Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
157340
CY2019Q1 celz Increase In Principal Balance Due To Penalty Provision
IncreaseInPrincipalBalanceDueToPenaltyProvision
0
CY2018Q1 celz Increase In Principal Balance Due To Penalty Provision
IncreaseInPrincipalBalanceDueToPenaltyProvision
12500
CY2019Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
265167
CY2018Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-7036772
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9437
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4799
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10961
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4135
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
55302
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18268
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-45000
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
44250
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-273015
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-164937
CY2019Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
575890
CY2018Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
254350
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
388436
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
253550
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
115421
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
88613
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
304056
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13697
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
419477
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102310
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
2357
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
200
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2019Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1187223
CY2018Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1887052
CY2019Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-357292
CY2018Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-154284
CY2019Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
168300
CY2018Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
CY2019Q1 celz Prepayment Premium Paid On Convertible Debt
PrepaymentPremiumPaidOnConvertibleDebt
19154
CY2018Q1 celz Prepayment Premium Paid On Convertible Debt
PrepaymentPremiumPaidOnConvertibleDebt
0
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-3994637
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
168975
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-3604780
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1018248
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1008088561
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
903311370
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1007488561
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
902711370
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2236173
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
217846
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1669207
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1877
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7586580
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-7933823
CY2019Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2019Q1 celz Management Reimbursement Agreementdescription
ManagementReimbursementAgreementdescription
At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice.
CY2019Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1020125
CY2019Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
972100
CY2019Q1 us-gaap Long Term Debt
LongTermDebt
1992225
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2018Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
800
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1877
CY2019Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
391614578
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8211; The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. &#160;Actual results could differ from those estimates.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2019Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
392000000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
142075119
CY2019Q1 celz Classofwarrantissued
Classofwarrantissued
5339804
CY2019Q1 celz Warrant Exercises
WarrantExercises
-79107585
CY2019Q1 celz Warrant Anti Dilution And Modification
WarrantAntiDilutionAndModification
0
CY2019Q1 celz Warrant Forfeitures Or Cancellations
WarrantForfeituresOrCancellations
-9698736
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
58608602
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0037
CY2019Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0
CY2018Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0
CY2018Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
110
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001187953
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
CELZ
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1043498850
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-027322-index-headers.html Edgar Link pending
0001144204-19-027322-index.html Edgar Link pending
0001144204-19-027322.txt Edgar Link pending
0001144204-19-027322-xbrl.zip Edgar Link pending
celz-20190331.xml Edgar Link completed
celz-20190331.xsd Edgar Link pending
celz-20190331_cal.xml Edgar Link unprocessable
celz-20190331_def.xml Edgar Link unprocessable
celz-20190331_lab.xml Edgar Link unprocessable
celz-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv521079_10q.htm Edgar Link pending
tv521079_ex31-1.htm Edgar Link pending
tv521079_ex31-2.htm Edgar Link pending
tv521079_ex32-1.htm Edgar Link pending
tv521079_ex32-2.htm Edgar Link pending